Related Experiment Video
Updated: Jul 14, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
[Genetic thrombophilia and cerebral venous thrombosis]
Alberto Romero1, Pascual Marco, José Verdú
1Unidad de Trombosis y Hemostasia, Servicio de Hematología y Hemoterapia, Hospital General Universitario de Alicante, Alicante, España. alberto0976@hotmail.com
Background And Objective:
Sinus cerebral venous thrombosis (SCVT) is an unfrequent disease, with variable clinical presentation and prognosis. The objective of this study was to analyze the relationship between factor V Leiden, prothrombin G20210A mutation (PT 20210A) and MTHR and SCVT.
Patients And Method:
Cases and control study including 15 patients with diagnosis of SCVT. We performed a genetic analysis of the mutation of factor V Leiden, the PT G20210A and the C677T of the MTHR.
Results:
Factor V Leiden: 26.6% heterozygote in cases and only 8.3% in control group, thus showing odds ratio [OR] = 4,0. Mutation 20210A of the prothrombin: in patients, 13.3% of heterozygote, while a 6,6% in controls, finding an OR = 2.1 (95% confidence interval [CI], 1.67-10.04). Mutation of the MTHR: 40% heterozygote and 20% homozygote in patients group respect to 51.6% and 6,9%, respectively, in the control group, but no statistical differences were found.
Conclusions:
The presence of factor V Leiden and PT 20210A are risk factors for SCVT, but not the mutation of the MTHR.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.